Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ transplant recipients (SOTR) are not well described in the literature. The objective of this analysis was to characterize 30-day hospitalization and other key secondary endpoints experienced by outpatient SOTR with mild–moderate COVID-19 treated with nirmatrelvir/ritonavir (NR), sotrovimab, or no SARS-CoV-2 specific treatment. This IRB-approved, retrospective study included 154 SOTR with a documented positive SARS-CoV-2 infection between December 16, 2021 and January 19, 2022 (a predominant Omicron BA.1 period in New York City). Patients who received NR (N = 28) or sotrovimab (N = 51) experienced a lower rate of 30-day hospitalization or death as compared to those who received no specific treatment (N = 75) (p = .009). A total of three deaths occurred, all among patients who initially received no specific treatment prior to hospitalization. These results suggest a role for SARS-CoV-2 specific agents in the treatment of SOTR with COVID-19, and that there does not appear to be any difference in effectiveness when comparing NR versus sotrovimab.

中文翻译：

---

Omicron BA.1 时代实体器官移植受者的 COVID-19 疗法和结果

文献中没有很好地描述与在实体器官移植受者 (SOTR) 中使用新型 COVID-19 疗法相关的治疗结果。该分析的目的是描述门诊 SOTR 患者经历的 30 天住院治疗和其他关键次要终点的特征，这些轻度至中度 COVID-19 患者接受了尼玛瑞韦/利托那韦 (NR)、sotrovimab 或无 SARS-CoV-2 特异性治疗。这项经 IRB 批准的回顾性研究包括 2021 年 12 月 16 日至 2022 年 1 月 19 日期间（纽约市主要的 Omicron BA.1 时期）154 名 SARS-CoV-2 感染记录呈阳性的 SOTR。接受 NR（N  = 28）或 sotrovimab（N = 51) 的 30 天住院率或死亡率低于未接受特殊治疗的患者 ( N  = 75) ( p  = .009)。总共发生了三例死亡，所有患者在住院前最初都没有接受过特殊治疗。这些结果表明 SARS-CoV-2 特异性药物在 COVID-19 的 SOTR 治疗中的作用，并且在比较 NR 与 sotrovimab 时似乎没有任何有效性差异。